Streamlining Eligibility Assessment for Alzheimer’s Disease-Modifying Therapies: Prediction of MMSE Scores Using the Digital Clock and Recall

Ali Seyed Jannati, Claudio Toro‐Serey, Marissa Ciesla, Emma Chen, John Showalter, David Bates, Alvaro Pascual-Leone, Sean TobynemedRxiv 2026 · DOI

TL;DR

Researchers have developed a machine learning "crosswalk" that predicts standard Mini-Mental State Examination (MMSE) scores using a 3-minute digital clock-drawing and recall test. The model matches the accuracy of human-administered tests while eliminating clinical bottlenecks and reducing the demographic biases that often prevent underrepresented groups from accessing new Alzheimer’s therapies.

What Problem Does This Paper Address?

The recent FDA approval of disease-modifying therapies (DMTs) like lecanemab and donanemab marks a turning point in Alzheimer’s care. However, these drugs have a strict "Goldilocks" window for eligibility: patients must typically score between 22 and 30 on the Mini-Mental State Examination (MMSE).

This creates two massive problems. First, the MMSE is a legacy paper-and-pencil test that takes 10–15 minutes to administer—a prohibitive length for primary care visits that often last less than 15 minutes total. This has led to a "specialist bottleneck," where wait times for evaluation can exceed four years, during which patients may "age out" of eligibility. Second, the MMSE is notoriously biased; it often penalizes individuals based on their education level or cultural background rather than their actual neuropathology.

Methods

The authors utilized Linus Health’s Digital Clock and Recall (DCR™), an FDA-listed tool that runs on an iPad with an Apple Pencil. Unlike a paper test that only evaluates the final drawing, the DCR captures the process of drawing with millisecond precision.

The team trained a Poisson elastic net regression model—a choice well-suited for "count" data like MMSE scores (0–30). The model analyzed:

  • Kinematics: Pen speed, acceleration, and "time off-tablet" (hesitation).
  • Acoustics: Pitch, jitter, shimmer, and speaking rate during the word recall phase.
  • Spatial Features: Symmetry and placement of clock components.
  • Demographics: Specifically, age was included as a predictor.

In total, the model evaluated roughly 300 digital metrics to "crosswalk" the DCR performance to a predicted MMSE score.

Datasets

The study relied on two major multi-site cohorts:

  1. Bio-Hermes-001 (N=945): This large dataset included cognitively unimpaired individuals, those with Mild Cognitive Impairment (MCI), and those with probable Alzheimer’s. It served as the primary training (70%) and testing (30%) set.
  2. Apheleia-001 (N=238): An independent external validation cohort used to test how well the model generalizes to new populations without further retraining.

Key Insights and Ideas

  • Process vs. Product: The "aha moment" here is that how a patient draws a clock (the micro-hesitations and motor planning) is often more revealing than the final image. These "process features" are more biologically grounded and less influenced by formal education than traditional MMSE questions (like "What is the date?").
  • The "Second Rater" Effect: The researchers didn't just look for high accuracy; they benchmarked the model against the MMSE’s own limitations. Since human-administered MMSE scores can fluctuate by 2–4 points on a retest, a model with a similar error margin is effectively as reliable as a human clinician.
  • Demographic Fairness: By filtering out "sociodemographic noise" through digital kinematics, the model maintained consistent accuracy across different racial and ethnic groups, suggesting it could be a more equitable gatekeeper for high-value care.

Key Results

  • High Accuracy: The model predicted MMSE scores with a Root Mean Squared Error (RMSE) of 2.31 in the training cohort and 2.62 in the external validation cohort.
  • Statistical Non-Inferiority: These error margins fall well within the 2–4 point test-retest reliability range of the manual MMSE itself.
  • Proven Fairness: Accuracy remained stable across demographics. For example, the RMSE for White participants (2.34) was nearly identical to that of Non-White participants (2.14).
  • Efficiency: The DCR can be administered by support staff in under 3 minutes, potentially allowing primary care clinics to screen millions of patients who currently face specialist backlogs.

Limitations and Future Work

The authors acknowledge that this study is cross-sectional, meaning it captures a snapshot in time. Future research is needed to determine if the model’s predicted scores can accurately track disease progression or treatment response longitudinally (over several years). Additionally, while the external validation was successful, the authors suggest further testing in broader, community-based populations to ensure the tool works for patients who aren't already enrolled in research studies.

Summary updated

Abstract

Abstract Introduction The eligibility of anti-amyloid disease-modifying therapies (DMTs) and their integration into clinical practice in some institutions requires a specific range of Mini-Mental State Examination (MMSE) scores. Reliance on this pencil-and-paper psychometric instrument imposes operational burdens and risks perpetuating health disparities due to the test’s known educational and cultural biases. This study evaluates the efficacy of the Digital Clock and Recall (DCR™) – a rapid, FDA-listed digital cognitive assessment – to crosswalk to MMSE scores using machine learning, thereby offering a faster, scalable, and equitable mechanism for patient triage. Methods We conducted a retrospective analysis using data from the multi-site Bio-Hermes-001 study ( NCT04733989 , N=945). Participants were clinically classified as cognitively unimpaired, mild cognitive Impairment, or probable Alzheimer’s dementia. We trained a Poisson elastic net regression model using age and multimodal digital features derived from the DCR (including drawing kinematics and voice acoustics) to predict MMSE scores. The model was tested for generalizability using an independent external validation cohort from the Apheleia study ( NCT05364307 , N=238). Results The machine learning model predicted MMSE scores with a root mean squared error (RMSE) of 2.31 in the training cohort. This error margin falls within the established test-retest reliability range of the manual MMSE itself (2–4 points), suggesting the prediction is statistically non-inferior to human administration. External validation in the Apheleia cohort demonstrated robust generalizability (RMSE = 2.62). Crucially, the model exhibited demographic fairness, maintaining consistent accuracy across Race (White RMSE = 2.34; Non-White RMSE = 2.14) and Ethnicity (Hispanic RMSE = 2.26; Non-Hispanic RMSE = 2.31). Discussion Machine learning can leverage multimodal features from the DCR to accurately and equitably crosswalk to MMSE scores in support of current guidelines, transforming a time-intensive manual test into a rapid, automated assessment. By deploying this “digital triage” engine, where traditional assessments are still used for DMT eligibility, healthcare systems can streamline the identification of DMT-eligible patients, reduce specialist referral bottlenecks, and ensure that access to life-altering therapies is determined by pathology rather than demography.
BibTeX
@misc{jannati2026streamlining,
  author = {Ali Seyed Jannati and Claudio Toro‐Serey and Marissa Ciesla and Emma Chen and John Showalter and David Bates and Alvaro Pascual-Leone and Sean Tobyne},
  title = {{Streamlining Eligibility Assessment for Alzheimer’s Disease-Modifying Therapies: Prediction of MMSE Scores Using the Digital Clock and Recall}},
  year = {2026},
  doi = {10.64898/2026.03.03.26347542},
  howpublished = {medRxiv},
}

Loading related content...

Figure